Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: A population-based study

American Journal of Human Genetics

Volumn 75, Issue 2, 2004, Pages 231-239

  Baser, Michael E ^a   Kuramoto, Lisa ^b   Joe, Harry ^b   Friedman, J M ^b   Wallace, Andrew J ^c   Gillespie, James E ^d   Ramsden, Richard T ^d   Evans, D Gareth R ^c  

^a University of British Columbia ^*  (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST MARY S HOSPITAL   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGE; AGED; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CANCER REGISTRY; CONTROLLED STUDY; CORRELATION ANALYSIS; CRANIAL NERVE TUMOR; DELETION MUTANT; DISEASE SEVERITY; FEMALE; FRAMESHIFT MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MISSENSE MUTATION; MOSAICISM; NERVOUS SYSTEM TUMOR; NEUROFIBROMATOSIS; NONSENSE MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PERIPHERAL NERVE TUMOR; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; REGRESSION ANALYSIS; SPINAL CORD TUMOR; UNITED KINGDOM;

EID: 3242661620     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/422700     Document Type: Article

References (44)

1. Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT, Evans DGR (2002a) Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 71:715-723
2. Baser ME, Kuramoto L, Joe H, Friedman JM, Wallace AJ, Ramsden RT, Evans DGR (2003) Genotype-phenotype correlations for cataracts in neurofibromatosis 2. J Med Genet 40:758-760
3. Baser ME, Makariou EV, Parry DM (2002b) Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2. J Neurosurg 96:217-222
4. Bruder CEG, Hirvela C, Tapia-Paez I, Fransson I, Segraves R, Hamilton G, Zhang XX, et al (2001) High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet 10:271-282
5. Bruder CEG, Ichimura K, Blennow E, Ikeuchi T, Yamaguchi T, Yuasa Y, Collins VP, Dumanski JP (1999) Severe phenotype of neurofibromatosis type 2 in a patient with a 7.4-MB constitutional deletion on chromosome 22: possible location of a neurofibromatosis type 2 modifier gene? Genes Chromosomes Cancer 25:184-190
6. Evans DGR, Birch JM, Ramsden RT (1999) Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 81:496-499
7. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992a) A clinical study of type 2 neurofibromatosis. Q J Med 84:603-618
8. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramsden R, Harris R (1992b) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841-846
9. Evans DGR, Trueman L, Wallace A, Collins S, Strachan T (1998a) Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 35:450-455
10. Evans DGR, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T (1998b) Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 63:727-736
11. Gardner WJ, Frazier CH (1930) Bilateral acoustic neuromas: a clinical study and field survey of a family of five generations with bilateral deafness in thirty-eight members. Arch Neurol Psychiatr 23:266-302
12. Gutmann DH, Geist RT, Xu H-m, Kim JS, Saporito-Irwin S (1998) Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet 7:335-345
13. Kluwe L, Beyer S, Baser ME, Hazim W, Haase W, Fünsterer C, Mautner V-F (1996) Identification of NF2 germ-line mutations and comparison with NF2 phenotypes. Hum Genet 98:534-538
14. Kluwe L, MacCollin M, Tatagiba M, Thomas S, Hazim W, Haase W, Mautner V-F (1998) Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet 77:228-233
15. Kluwe L, Mautner V-F (1996) A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. Hum Genet 97:224-227
16. - (1998) Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet 7:2051-2055
17. Kluwe L, Mautner V-F, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, MacCollin M (2003) Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 40:109-114
18. Lee DK, Abbott ML (1969) Familial central nervous system neoplasia: case report of a family with von Recklinghausen's neurofibromatosis. Arch Neurol 20:154-160
19. Lopez-Correa C, Zucman-Rossi J, Brems H, Thomas G, Legius E (2000) NF2 gene deletion in a family with a mild phenotype. J Med Genet 37:75-77
20. MacCollin M, Mautner V-F (1998) The diagnosis and management of neurofibromatosis 2 in childhood. Semin Pediatr Neurol 5:243-252
21. Mautner V-F, Baser ME, Kluwe L (1996a) Phenotypic variability in two families with novel splice-site and frameshift NF2 mutations. Hum Genet 98:203-206
22. Mautner V-F, Baser ME, Thakkar SD, Feigen UM, Friedman JM, Kluwe L (2002) Vestibular schwannoma growth in patients with neurofibromatosis type 2: a longitudinal study. J Neurosurg 96:223-228
23. Mautner V-F, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W, Samii M, Wais R, Pulst S-M (1996b) The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 38:880-886
24. Mautner V-F, Lindenau M, Baser ME, Kluwe L, Gottschalk J (1997) Skin abnormalities in neurofibromatosis; 2. Arch Dermatol 133:1539-1543
25. Mautner V-F, Tatagiba M, Guthoff R, Samii M, Pulst S-M (1993) Neurofibromatosis in the pediatric age group. Neurosurgery 33:92-96
26. Mautner V-F, Tatagiba M, Lindenau M, Funsterer C, Pulst S-M, Baser ME, Kluwe L, Zanella FE (1995) Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol 165:951-955 (erratum 166:1231)
27. Mérel P, Hoang-Xuan K, Sanson M, Bijlsma E, Rouleau G, Laurent-Puig P, Pulst S, Baser M, Lenoir G, Sterkers JM, Philippon J, Resche F, Mautner V-F, Fischer G, Hulsebos T, Aurias A, Delattre O, Thomas G (1995) Screening for germline mutations in the NF2 gene. Genes Chromosomes Cancer 12:117-127
28. Moyhuddin A, Baser ME, Watson C, Purcell S, Ramsden RT, Heiberg A, Wallace AJ, Evans DGR (2003) Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 40:459-463
29. Nunes F, MacCollin M (2003) Neurofibromatosis 2 in the pediatric population. J Child Neurol 18:718-724
30. Otsuka G, Saito K, Nagatani T, Yoshida J (2003) Age at symptom onset and long-term survival in patients with neurofibromatosis type 2. J Neurosurg 99:480-483
31. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas E, Pikus A, Patronas N (1994) Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:450-461
32. Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M, Eldridge R, Gusella JF (1996) Germline mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 59:529-539
33. Patronas NJ, Courcoutsakis N, Bromley CM, Katzman GL, MacCollin M, Parry DM (2001) Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology 218:434-442
34. Rouleau GA, Mérel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Bijlsma E, Fashold R, Dumanski J, de Jong P, Parry D, Eldridge R, Aurias A, Delattre O, Thomas G (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363:515-521
35. Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han F-y, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, Michels V, Riccardi VM, Weksberg R, Kitamura K, Bradburn JM, Hall BD, Propping P, Rouleau GA (1996) Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 59:331-342
36. Scoles D, Chen M, Pulst S-M (2002) Effects of NF2 missense mutations on schwannomin interactions. Biochem Biophys Res Commun 290:366-374
37. Scoles DR, Baser ME, Pulst S-M (1996) A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes. Neurology 47:544-546
38. Scoles DR, Huynh DP, Morcos PA, Coulsell ER, Robinson NGG, Tamanoi F, Pulst S-M (1998) Neurofibromatosis 2 tumour suppressor schwannomin interacts with βII-spectrin. Nat Genet 18:354-359
39. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short MP, Buckler AJ, Gusella JF (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791-800 (erratum 75:826)
40. Wallace AJ, Wu C-L, Elles RG (1999) Meta-PCR: a novel method for creating chimaeric DNA molecules and increasing the productivity of mutation screening techniques. Genetic Testing 3:173-183
41. Wishart JH (1822) Case of tumours in the skull, dura mater, and brain. Edinburgh Med Surg J 18:393-397
42. Yau SC, Bobrow M, Mathew CG, Abbs SJ (1996) Accurate diagnosis of carriers of deletions and duplications in Duchenne/Becker muscular dystrophy by fluorescent dosage analysis. J Med Genet 33:550-558
43. Zhao Y, Kumar RA, Baser ME, Evans DG, Wallace A, Kluwe L, Mautner V-F, Parry DM, Rouleau GA, Joe H, Friedman JM (2002) Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2). Genet Epidemiol 23:245-259
44. Zucman-Rossi J, Legoix P, Sarkissian HD, Cheret G, Sor F, Bernardi A, Cazes L, Giraud S, Ollagnon E, Lenoir G, Thomas G (1998) NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet 7:2095-2101